Barber buzzes into Aquestive CEO post as Kendall leaves amid FDA delay

Aquestive Therapeutics is shuffling its deck of executives as it awaits an FDA decision on its seizure drug, parting company with CEO Keith Kendall and promoting Daniel Barber to fill the gap created by the exit.